Anti-Anxiety Agents , Autistic Disorder , Humans , Buspirone/therapeutic use , Autistic Disorder/complications , Autistic Disorder/drug therapy , Anxiety Disorders/complications , Anxiety Disorders/drug therapy , Anxiety Disorders/epidemiology , Anxiety/complications , Anxiety/drug therapy , Comorbidity , Anti-Anxiety Agents/therapeutic use , Double-Blind Method
Suicide rates among adolescents and young adults have been increasing in the last decade. The current knowledge of the warning signs, risk factors, and the use of screening tools has many gaps. There are many views from within, critics, survivors, and advocacy groups to focus more on the contextual understanding of symptomatology. In clinical practice, many of these high-risk groups fail to raise the red flags due to the complex and ambiguous nature of presentations. Therefore, these groups need greater attention, and given their counter-initiative nature, they challenge the current approaches to address suicidality in adolescents and young adults.
The delusional misidentification syndromes (DMS) have been described extensively in the descriptive literature of the last century given its unusual and often-distressing clinical presentations. In the last few decades, there have been advances in scientific research that have identified more precise brain areas involved in these delusional syndromes. Since DMS are reported in both early-onset psychosis and neurodegenerative conditions, the strategies to address and mitigate underlying etiology warrant a thorough assessment and individualized treatment planning. The age of onset, nature of the clinical presentation, the utility of diagnostic tests, and assessment of violence are few among many areas which need attention during clinical management of these rare syndromes.